Analyst Holds Steady On Curis As FDA Removes Partial Clinical Hold On Leukemia Study
Portfolio Pulse from Vandana Singh
The FDA has removed the partial clinical hold on Curis Inc's TakeAim Leukemia Phase 1/2 study of emavusertib for hematologic malignancies. The recommended phase 2 dose for emavusertib has been established. HC Wainwright maintains its Buy rating for Curis but lowers the price target to $6 from $9 due to delayed launch expectations for AML/MDS and the dilution associated with the recent capital raise. The analyst forecasts a launch for emavusertib for AML/MDS in late 2027, with sales of $23.3 million that year, growing to $452 million in 2029.
July 07, 2023 | 5:28 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The FDA's removal of the clinical hold on Curis Inc's leukemia study is a positive development. However, HC Wainwright's lowered price target due to delayed launch expectations and recent capital raise dilution may negatively impact the stock price.
The FDA's decision to lift the clinical hold on Curis's leukemia study is a positive development for the company, potentially leading to increased investor confidence. However, HC Wainwright's decision to lower its price target for Curis due to delayed launch expectations and dilution from a recent capital raise could negatively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100